Navigation Links
The Scientific Business of Thomson Reuters Publishes Three Pharma Matters Reports Covering the First Quarter of 2008

Quarterly Reports use Market Intelligence and Competitive Analysis from Thomson Reuters to Explore Various Aspects of the Pharmaceutical Pipeline

LONDON and PHILADELPHIA, Aug. 18 /PRNewswire/ -- Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, has announced the availability of the Pharma Matters reports covering the time period January-March 2008. Launched more than two years ago, the quarterly Pharma Matters reports cover all aspects of the pharmaceutical pipeline, leveraging strategic intelligence and competitive analysis from Thomson Pharma(R), Newport Horizon Premium(TM) and the Thomson Messaging Mapping System(SM).

The Ones to Watch -- A Thomson Reuters quarterly review of the latest phase changes in the pharmaceutical pipeline, this report is based on the strategic data and analysis from Thomson Pharma, the world's leading pharmaceutical competitive intelligence solution. In the report covering Q1 2008, the top five most promising drugs launched or receiving approval were:


Intelence(TM) HIV-1 infection Tibotec

Pristiq(TM) Depression Wyeth

Ionsys(TM) Acute pain ALZA

Arcalyst(TM) CIAS1-associated Regeneron

periodic syndromes

Moxatag(TM) Streptococcus MiddleBrook


pharyngitis, tonsillitis

More analysis, as well as information on drugs entering clinical Phases I, II and III, are available in the full report: -march_08.pdf

(Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your Internet browser's URL address field. Remove the space if one exists.)

Movers and Shakers -- Introduced in mid-2007, this report is the newest in the Pharma Matters series and covers the U.S. generics industry using data and analysis from Newport Horizon Premium, the critical product targeting the global business development system. Analysis from the Q1 2008 report includes:
-- The U.S. generics market is remarkably robust but will be hit by the

current downturn in drugs innovation, which will translate into a

decline in off-patent drugs from 2012.

-- 'Super Generic' companies such as Teva and Mylan now dominate the

generics market and will be the best placed to survive any future


-- During the first quarter of 2008, final approvals were issued on 134

'A'-rated ANDAs, up from 108 the quarter before.

-- 11 new products (four combination products and seven single active

ingredient products) were subjected to paragraph IV challenges for the

first time in Q1 2008, in comparison to the challenges made to seven

new products in the last quarter of 2007.

-- During the first quarter of 2008, the largest number of ANDA approvals

went to US-based companies. Thirty different US-based corporations

received a total of 59 final ANDA approvals.

-- In the same time period, fourteen India-based companies received a

total of 36 approvals, putting India in second place.

To learn more about companies making their mark on the U.S. generics market, click on this link to read the full report: jan-mar08.pdf

(Due to the length, copy and paste URL into browser window.)

Who is Making the Biggest Splash? -- This report is a Thomson Reuters expert review of the organizations that are helping to shape professional opinions on drugs and therapies, using the unique insights of the Thomson Message Mapping System. In this quarterly review of the scientific literature on drugs and therapies, Thomson Reuters assesses the quantity and quality of the materials published by pharmaceutical companies, research institutions and other non-commercial bodies. The top five of the listed 15 organizations that have made the biggest impact as the leading sources of information on medical research from January-March 2008 are:

1. Eli Lilly

2. sanofi-aventis

3. Novartis

4. Bristol-Myers Squibb

5. GlaxoSmithKline

To see the complete list, as well as analysis and methodology, click to read the full report: -splash-mar2008.pdf

(Due to the length, copy and paste URL into browser window.)

To sign up for the Thomson Reuters Pharma Matters series of publications visit:

About Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. For more information, go to

SOURCE Thomson Reuters
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
2. Thomson Scientific Predicts Nobel Laureates
3. Genaera Announces Formation of Scientific Advisory Board for Obesity Drug Candidate Trodusquemine (MSI-1436)
4. Thomson Scientific Announces BONDplus for Biological Researchers
5. Milestone Scientific Commences Declaratory Judgment Action With Respect to Its Single Tooth Anesthesia (STA(TM)) System and Compudent(TM) System
6. International Society of Hair Restoration Surgery Hosts 15th Annual Scientific Meeting in Las Vegas, September 26-30, 2007
7. Milestone Scientific Names Robert Presutti New Vice President of Sales and Marketing
8. Thomson Scientific Signs Multi-Year Agreement with The Council for Scientific and Industrial Research (CSIR)
9. Heart Failure Society of America 11th Annual Scientific Meeting to Focus on Heart Failure Guidelines, Innovation and New Research
10. Milestone Scientific to Exhibit the STA(TM) System at the American Dental Associations 148th Annual Session in San Francisco
11. Delta Dental Plans Association Forms National Scientific Advisory Committee
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... For many X-rays taken ... for accurate interpretation by the radiologist. The marking utensils are so small, however, ... has found a way to alleviate this problem. , He developed the patent-pending ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... of Excellence (BHCOE) today announced that the organization has awarded Education and Developmental ... with a Distinguished Award. The award celebrates exceptional special needs providers that excel ...
(Date:12/1/2015)... MA (PRWEB) , ... December 01, 2015 , ... Lutronic, ... release of Clarity, the latest addition to the devices for sale in the United ... 755 nm Alexandrite and long-pulsed 1064 nm Nd:YAG lasers, into a single platform that ...
(Date:12/1/2015)... Menlo Park, CA (PRWEB) , ... December 01, 2015 , ... ... Challenge (XTC) has selected 10 semi-finalists to head to Las Vegas for CES 2016, ... distinguished judges including CEO of Consumer Technology Association Gary Shapiro, Founding Partner of Pacific ...
(Date:12/1/2015)... China (PRWEB) , ... December 01, 2015 , ... Nurotron ... result in its largest order to date. , The order will be from ... systems. Nurotron’s Venus Cochlear Implant System is an effective solution for children and adults ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 1, 2015 Array BioPharma Inc. ... its Chief Executive Officer, Ron Squarer ... Healthcare Conference in New York.  The public ... through a webcast on the Array BioPharma ... --> , ...
(Date:12/1/2015)... 2015 Assurex Health, Inc. today announced ... healthcare providers an expanded range of options in ... from depression, anxiety, bipolar disorder, posttraumatic stress disorder ... i .   --> ... addition of two new drug classes, 17 FDA-approved ...
(Date:12/1/2015)... 2015 --> ... "Nucleic Acid Labeling Market by Product (Reagents & Kits, ... In Vitro Transcription, Reverse Transcription, End Labeling), by Region ... global market is expected to reach USD 1,925.7 Million ... at a CAGR of 8.65%. Browse 77 ...
Breaking Medicine Technology: